Guangzhou Kingmed Diagnostics Group Co Ltd
Guangzhou Kingmed Diagnostics Group Co., Ltd. provides medical diagnosis services in China. It also provides health check-up, cold chain logistics, and other services. Guangzhou Kingmed Diagnostics Group Co., Ltd. was founded in 2006 and is headquartered in Guangzhou, China.
Guangzhou Kingmed Diagnostics Group Co Ltd (603882) - Net Assets
Latest net assets as of September 2025: CN¥6.95 Billion CNY
Based on the latest financial reports, Guangzhou Kingmed Diagnostics Group Co Ltd (603882) has net assets worth CN¥6.95 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.71 Billion) and total liabilities (CN¥2.76 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.95 Billion |
| % of Total Assets | 71.59% |
| Annual Growth Rate | 35.02% |
| 5-Year Change | 92.83% |
| 10-Year Change | 678.78% |
| Growth Volatility | 40.24 |
Guangzhou Kingmed Diagnostics Group Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Guangzhou Kingmed Diagnostics Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangzhou Kingmed Diagnostics Group Co Ltd (2012–2024)
The table below shows the annual net assets of Guangzhou Kingmed Diagnostics Group Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.48 Billion | -12.55% |
| 2023-12-31 | CN¥8.55 Billion | -3.69% |
| 2022-12-31 | CN¥8.87 Billion | +36.06% |
| 2021-12-31 | CN¥6.52 Billion | +68.26% |
| 2020-12-31 | CN¥3.88 Billion | +66.68% |
| 2019-12-31 | CN¥2.33 Billion | +18.93% |
| 2018-12-31 | CN¥1.96 Billion | +12.12% |
| 2017-12-31 | CN¥1.74 Billion | +53.86% |
| 2016-12-31 | CN¥1.13 Billion | +18.10% |
| 2015-12-31 | CN¥959.84 Million | +145.03% |
| 2014-12-31 | CN¥391.72 Million | +51.59% |
| 2013-12-31 | CN¥258.41 Million | +26.87% |
| 2012-12-31 | CN¥203.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Kingmed Diagnostics Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 35406.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.42 Billion | 73.99% |
| Common Stock | CN¥463.26 Million | 6.32% |
| Other Components | CN¥1.44 Billion | 19.69% |
| Total Equity | CN¥7.33 Billion | 100.00% |
Guangzhou Kingmed Diagnostics Group Co Ltd Competitors by Market Cap
The table below lists competitors of Guangzhou Kingmed Diagnostics Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wave Life Sciences Ltd
NASDAQ:WVE
|
$1.10 Billion |
|
SHOU. HLDGS. LTD. (BL)
F:SHVA
|
$1.10 Billion |
|
Guangdong Shenglu Telecommunication Tech Co Ltd
SHE:002446
|
$1.10 Billion |
|
Perella Weinberg Partners
NASDAQ:PWP
|
$1.10 Billion |
|
Wilhelm Wilhelmsen Holding ASA
LSE:0P0T
|
$1.10 Billion |
|
Zhejiang Windey Co Ltd
SHE:300772
|
$1.10 Billion |
|
Sinochem International Corp
SHG:600500
|
$1.10 Billion |
|
ATAI Life Sciences BV
NASDAQ:ATAI
|
$1.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Kingmed Diagnostics Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,362,834,963 to 7,325,269,947, a change of -1,037,565,016 (-12.4%).
- Net loss of 381,241,138 reduced equity.
- Dividend payments of 419,565,421 reduced retained earnings.
- Share repurchases of 210,001,542 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-381.24 Million | -5.2% |
| Dividends Paid | CN¥419.57 Million | -5.73% |
| Share Repurchases | CN¥210.00 Million | -2.87% |
| Other Changes | CN¥-26.76 Million | -0.37% |
| Total Change | CN¥- | -12.41% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Kingmed Diagnostics Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 53.11x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.53 | CN¥27.91 | x |
| 2013-12-31 | CN¥0.67 | CN¥27.91 | x |
| 2014-12-31 | CN¥1.09 | CN¥27.91 | x |
| 2015-12-31 | CN¥2.69 | CN¥27.91 | x |
| 2016-12-31 | CN¥2.85 | CN¥27.91 | x |
| 2017-12-31 | CN¥4.15 | CN¥27.91 | x |
| 2018-12-31 | CN¥4.16 | CN¥27.91 | x |
| 2019-12-31 | CN¥4.97 | CN¥27.91 | x |
| 2020-12-31 | CN¥8.20 | CN¥27.91 | x |
| 2021-12-31 | CN¥13.52 | CN¥27.91 | x |
| 2022-12-31 | CN¥18.47 | CN¥27.91 | x |
| 2023-12-31 | CN¥17.94 | CN¥27.91 | x |
| 2024-12-31 | CN¥15.76 | CN¥27.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Kingmed Diagnostics Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.30%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.42x
- Recent ROE (-5.20%) is below the historical average (18.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 24.26% | 4.51% | 1.55x | 3.46x | CN¥25.91 Million |
| 2013 | 22.49% | 3.87% | 1.58x | 3.69x | CN¥29.13 Million |
| 2014 | 18.86% | 3.85% | 1.32x | 3.71x | CN¥33.27 Million |
| 2015 | 15.09% | 5.87% | 1.19x | 2.15x | CN¥47.32 Million |
| 2016 | 15.45% | 5.28% | 1.21x | 2.42x | CN¥60.00 Million |
| 2017 | 11.07% | 4.97% | 1.14x | 1.95x | CN¥18.28 Million |
| 2018 | 12.25% | 5.16% | 1.14x | 2.08x | CN¥42.79 Million |
| 2019 | 17.69% | 7.64% | 1.20x | 1.93x | CN¥174.85 Million |
| 2020 | 39.86% | 18.31% | 1.24x | 1.75x | CN¥1.13 Billion |
| 2021 | 35.21% | 18.58% | 1.11x | 1.71x | CN¥1.59 Billion |
| 2022 | 31.92% | 17.80% | 1.11x | 1.61x | CN¥1.89 Billion |
| 2023 | 7.69% | 7.53% | 0.73x | 1.41x | CN¥-192.90 Million |
| 2024 | -5.20% | -5.30% | 0.69x | 1.42x | CN¥-1.11 Billion |
Industry Comparison
This section compares Guangzhou Kingmed Diagnostics Group Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,767,087,259
- Average return on equity (ROE) among peers: 6.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Kingmed Diagnostics Group Co Ltd (603882) | CN¥6.95 Billion | 24.26% | 0.40x | $1.10 Billion |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |